On February 1, 2024, Fractyl Health, a metabolic therapeutics company focused on pioneering new approaches for the treatment of type 2 diabetes (T2D) and obesity, announced the pricing of its initial public offering of 7,333,333 shares of common stock at a public offering price of $15.00 per share, for total gross proceeds of approximately $110.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Fractyl Health. Wilson Sonsini Goodrich & Rosati advised Fractyl Health on patent matters related to the transaction.

All of the common stock is being offered by Fractyl Health. The offering is expected to close on February 6, 2024, subject to customary closing conditions. In addition, Fractyl Health has granted the underwriters a 30-day option to purchase up to an additional 1,099,999 shares of its common stock at the initial public offering price less the underwriting discounts and commissions. Fractyl Health’s common stock is expected to begin trading on the Nasdaq Global Market on February 2, 2024, under the ticker symbol “GUTS.”

The Wilson Sonsini team that advised Fractyl Health on patent matters related to the transaction included Peter Eng, Clark Lin, and Darby Chan.

For more information, please see Fractyl Health’s press release.